Siglec-1 is highly expressed by circulating myeloid and local lymph node cells41,42 and targeted delivery of microbial/tumor antigens through Siglecs has shown promise for inducing effective T cell and induced natural killer cells (iNKT) activation.43,44 Recently it has also been shown that Siglec-1 plays an important role in phagocytosis, and in primary IFN and early cytokine production after challenge with sialylated pathogens.26,27,45 We also demonstrate a direct role for Siglec-1 in promoting uptake of C. jejuni strains from GBS patients but not strains from colitis patients. Here, IFNA1 is linked to Guillain-Barre syndrome.